Development Of Melittin- Based Nanocarriers for Targeted Cancer Therapy

Peptides found in bee venom, particularly melittin, have shown promise as natural anticancer medicines. These peptides exert their anticancer effects by compromising cellular membranes, initiating programmed cell death, and influencing the function of the immune system. The clinical use of melittin is limited due to notable toxicity and insufficient molecular stability, even though it holds considerable therapeutic promise. By creating melittin-based nanocarriers including polymeric nanoparticles, liposomes, and nano emulsions, recent developments in nanotechnology have overcome these constraints and made it possible for precise tumour targeting, regulated drug release, and biocompatible delivery. These engineered platforms enhance the therapeutic efficacy of melittin while minimizing systemic toxicity and improving pharmacokinetic behaviour. Further functionalization with tumour-specific ligands and combination with other therapeutic modalities amplifies the effectiveness and overcomes drug resistance. Therefore, bee venom peptide is being transformed into promising tools for targeted cancer therapy through nanotechnology-driven delivery, bridging the gap between conventional methods and state-of-the-art nanomedicine..